Tumor-associated tertiary lymphoid structures: gene-expression profiling and their bioengineering

Despite the clinical success with antibodies against CTLA-4 and PD-1, cytokines (e. g., high-dose interleukin-2), as well as the adoptive transfer of tumor-infiltrating lymphocytes (TILs), many patients treated with those agents fail to respond in a clinically meaningful manner. Employing Moffitt Cancer Center’s revolutionary Total Cancer Care (TCC) bio-repository (> 38, 000 tumors), genomic database (> 16, 000 tumor gene-expression arrays; ~5, 000 tumor whole genome, whole exome, and targeted gene sequences), and longitudinal clinical database (on > 100, 000 TCC consented patients), we identified a unique 12-chemokine (CCL2, CCL3, CCL4, CCL5, CCL8, CCL18, CCL19, CCL21, CXCL9, CXCL10, CXCL11, and CXCL13) gene-expression signature (GES) from a metagene grouping with overwhelming enrichment for immune-related and inflammation-related genes. The GES was interrogated on 14, 492 distinct solid tumors of 24 distinct tissue types (primaries and metastases) in TCC (modified Affy chip) and confirmed on another set of > 7, 000 samples in the TCGA database (RNASeq) and showed distribution across different histologies, including breast, lung, melanoma, and colorectal cancers of differing degrees ( 1 – 4 ). We showed that this 12-chemokine GES could accurately predict the degree and type of lymphoid infiltrate, organized remarkably as tumor-localized, tertiary lymphoid structures (TL-TLSs) that comprise—by immunohistochemistry staining—prominent B cell follicles, T cell marginal zones, and associated follicular dendritic cells (DCs) but few, if any, T regulatory cells ( 2 – 4 ). TL-TLSs appear to exhibit similar structural and cellular characteristics of peripheral lymph nodes and presumably arise in the tumor microenvironment in response to chronic inflammation ( 5 – 7 ).

Of importance, there was a highly significant and consistent association between a marked increase in overall patient survival, the value of the mean score of the GES, and the presence of TL-TLSs in stage IV (non-locoregional) melanoma, colorectal cancer, and, most recently, in stage IV bladder cancer, non-small cell lung cancer, and certain types of breast cancer, especially in basal and HER2 ⁺ patients. Moreover, we have now demonstrated that solid tumor radiosensitivity across a spectrum of histologies is associated with immune activation as measured by the GES ¹ ( 8 ). It remains unclear whether TLSs are either only a consequence of an immune response per se or sites of an active immune reaction against the local tissue components. With respect to the latter, previous studies showed that TLSs are associated with longer survival of cancer patients, aggravation of graft rejection, and presence of auto-immune inflammatory disease ( 9 ). TLSs have also been observed as a consequence of immunization with certain vaccines. As examples, intramuscular vaccination targeting HPV16 in patients with cervical intraepithelial neoplasia induced cervical tissue immune infiltrates, including organized TLSs ( 10 ). In a pancreatic ductal adenocarcinoma clinical trial, an irradiated, allogeneic granulocyte-macrophage colony-stimulating factor-secreting pancreatic tumor cell vaccine converted an “ non-immunogenic” neoplasm into an “ immunogenic” one by inducing formation of TLSs ( 11 ). Gene-expression analysis of the vaccine-induced TLSs showed a suppressed Treg pathway and an enhanced Th17 pathway, which was associated with improved patient survival and elicitation of mesothelin-specific T-cell responses. In another study in mice with deficiency of secondary lymphoid organs, infection of influenza virus could stimulate neogenesis of lung TLSs that produced an efficient protective immune response ( 12 ). Collectively, these studies argue indirectly in favor of an active participatory role of TLSs in effective immune responses. Therefore, local induction of TLSs in the tumor microenvironment could be a promising therapeutic strategy to exploit against cancer.

We believe this unique GES may potentially be used for preselecting cancer patients for broad immunotherapy interventions (e. g., vaccines, cytokines, and/or immunoregulatory antibodies) to increase clinical response rates by identifying the presence of antitumor reactive, TLSs existing within tumor masses. Clinical trials in melanoma patients are pending to test this hypothesis. In addition, this GES is currently being used to potentially identify solid tumor masses, beyond melanoma, capable of providing effective TILs for ex vivo expansion for adoptive transfer into patients ( 13 ). The existence of a functional connection between TL-TLSs and identifying (and expanding) tumor-specific, therapeutic TIL is underway. Finally, in collaboration with Eli Pikarsky at the Hadassah Medical Center, we are investigating why patients with certain GES-positive solid tumors with TL-TLSs (i. e., hepatocellular carcinoma) actually show poor prognosis, suggesting that not all TL-TLSs are beneficial.

The 12-chemokine GES has now also provided the actual gene leads for potentially constructing bioengineered “ designer lymph nodes.” The novel platform is based on the improvement, manipulation, and stimulation of the host’s own immune system. We are using a specialized antigen-presenting DC, produced from the host’s blood or bone marrow, which is both antigen(s) loaded and genetically manipulated to express highly selected chemokine genes combined with biomaterial scaffolds prior to administration into cancer-bearing hosts ( 14 ). This gene-modified cell-scaffold platform “ design builds” a functioning “ lymph node” on its own at any administration site that then produces a preplanned immunologic response against cancer cells locally and then throughout the host’s body. The technology includes the option of providing gene-modified cell-scaffold platforms at multiple, independent sites to create multiple, independent “ lymph nodes” of the same function and specificity concurrently. The administrations can also be staggered to create additional new structures over time. Moreover, by administering pools of different gene-modified cell-scaffold platforms, we hypothesize that these structures will act independently of each other and will create distinct functioning “ lymph nodes” in the same host. Utilized by the host, these “ designer lymph nodes” can provide an enhanced, unified, or diversified immune system to fight cancer.

Tertiary lymphoid structures have been described in animal models. Previous studies on gene knockout mice have identified the role of lymphotoxin (LT) in development of lymphoid organs ( 15 ). LTα-deficient mice, which lack the soluble LTα3 homotrimer as well as the membrane LTα1β2 heterotrimer, show absence of Peyer’s patches and all peripheral lymph nodes ( 16 , 17 ). LTβ-deficient mice also displayed similar defect with residual mesenteric and cervical lymph nodes ( 18 ). Consistently, transgenic mouse models that ectopically express LTα or LTβ demonstrate formation of TLSs in non-lymphoid tissues. For instance, restricted expression of LTα or LTα/LTβ in kidney and pancreas induced organized infiltrates in these sites that show similar cellular composition to lymphoid organs. T cells, B cells, plasma cells, antigen-presenting cells, and features of high-endothelial venules (HEV) were observed in the infiltrates ( 19 , 20 ). These studies suggest that the formation of TLSs involves the same signaling pathways in development of the secondary lymphoid organs.

In addition to the LT pathway, several transgenic mouse models with overexpression of chemokines that are important for recruiting immune cells displayed TLSs. In a transgenic mouse model with pancreatic islet-specific expression of CCL21, spontaneous development and organization of lymphoid tissues composed of T cells, DC, B cells, HEV, and stroma reticulum was observed ( 21 , 22 ). Similarly, constitutive expression of CCL21 in thyroid resulted in significant lymphocytic infiltrates, which are topologically arranged into B and T cell areas ( 23 ). In addition to CCL21, ectopic expression of another three important homeostatic chemokines CCL19, CXCL12, and CXCL13 in pancreatic islet led to formation of TLSs with different size, cellular composition, and organization ( 24 , 25 ). Moreover, in a recent study, transplantable and functional “ artificial” TLSs could be constructed from slow-releasing gels containing different lymphogenesis-related chemokines and ligands ( 26 ). Collectively, these studies indicated that the formation of TLSs could be achieved by chemokine-mediated accumulation of lymphocytes.

Sound preclinical models of TLS formation are being developed in which multiple elements are being interrogated for the capacity to recruit and design an antitumor immune system. The inclusion of lymph node-derived primary cellular components, which normally provide chemotactic and homeostatic cues in conventional lymph nodes ( 27 ), are being genetically modified to express selected chemotactic and lymphoid neogenesis-related genes to enhance TLS formation. Previous studies have suggested that inclusion of activated DCs in a stromal cell-induced TLS model could markedly enhance the efficiency and organization of TLS formation ( 28 ). The contributions of DCs to TLS induction have been reviewed elsewhere ( 29 ). In this regard, CD11c ⁺ DCs were necessary for maintenance of inducible bronchus-associated lymphoid tissues. Additionally, retinoic acid production by DCs from gut-associated lymphoid organs was involved in the imprinting of gut-homing receptors on activated T cells. Various modified cell lines are being combined with tumor antigen-pulsed DCs and then incorporated in biocompatible scaffold materials and administered to tumor-bearing mice as injectable or implantable matrices. These matrices should serve as model systems to better understand the factors governing the formation and/or maintenance of TLSs and also to identify and classify tumor-specific, therapeutic TIL. Additionally, these matrix-based systems may function as a therapeutic platform by delivering, stimulating, and expanding transplanted lymphocytes and/or modified DCs.

Scaffolds are typically three-dimensional microporous structures designed to enable ex vivo cell encapsulation and/or in vivo cell infiltration while providing mechanical support, cell adhesion, and a sustained supply of biological cues to promote cell migration and interactions ( 30 , 31 ). The scaffolds must be biocompatibile and should maintain a robust state for adequate time to allow the development of a new tissue, while eventually undergoing degradation and be replaced by the new tissue. Based on the origin of materials, scaffolds can be classified into synthetic or natural polymeric systems ( 32 ). We have developed optical means by which to track the fate of implanted materials ( 33 ) and embedded cells fate ( 34 ) non-invasively over time. This enables us to study cell: material interactions in vivo and to rationally modify the materials, as needed, to attain the desired preclinical outcomes.

Synthetic polymers can be readily tailored and modified to provide excellent mechanical and chemical properties; however, they typically lack essential biological elements that are required to induce necessary cell responses. For example, poly(lactic acid), poly(glycolic acid), and poly(caprolactone) are the most widely used synthetic biodegradable polymers, but their hydrophobic nature limits their application in tissue engineering due to the insufficient water absorption, cell adhesion, and interactions. In contrast, hydrophilic synthetic polymers such as poly(ethylene glycol) (PEG) and poly(ethylene oxide) possess excellent solubility in a wide range of solvents. However, they are not biologically degradable; therefore, they can only be used as permanent implants or as low-molecular weight blocks in combination with other components to enable elimination from the body ( 35 ).

Natural polymers are particularly attractive candidates for tissue-engineering applications, as they offer excellent biocompatibility. Unlike synthetic polymers, they can be biologically degraded into components, which are non-inflammatory or non-toxic. The reactive sites available in most of the natural polymers allow ligand conjugation, cross-linking, and other modifications to tune their properties for specific applications ( 36 ). Protein-based natural polymers such as collagen and gelatin have the potential to control the cellular migration, proliferation, and organization during new tissue development, as they possess many features of extracellular matrix. However, they often suffer from batch-to-batch variations due to the difficulties associated with the purification processes. Polysaccharides (alginate, chitosan, starch, and hyaluronic acid derivatives) are another promising class of natural and biocompatible polymers. Chitosan in particular is an important example with an established safety profile in humans ( 37 , 38 ).

In addition, a diverse collection of hybrid scaffolds using different combinations of synthetic and natural polymers has been developed for specific tissue-engineering applications. As examples, a polyurethane scaffold containing type I collagen and matrigel was used to create 3D lymph node T zone stromal models ( 39 ). A different hybrid scaffold approach incorporating a collagen matrix into PEG hydrogel was used by Stachowiak and Irvine to improve the migration of loaded T cells and DCs within the framework ( 40 ). When needed, scaffolds can be doped with microparticles or nanoparticles for controlled release of soluble factors in addition to serving as a scaffold for cells. Such measures can provide sustained environmental cues to augment antigen-presenting DCs or lymphocyte longevity, maturation, and activation. Hence, synthetic materials can be modified to include biological cues and harbor sites for cells to serve as engineered scaffolds, which can be manufactured in a reproducible manner and with controlled properties. Hydrogels, in particular, can provide a controlled cell microenvironment for immune cells that enable the recruitment, expansion, and activation of immune cells ex vivo and in vivo ( 41 ). The choice of materials is dictated by the end use, including biocompatibility, immunogenicity, site of implantation, types of stimuli, and release kinetics. Hydrogels have been utilized in both active and passive immunotherapies. They can be used to deliver antigens, chemokines, and other factors to DCs, to induce T cell stimulation and B cell-mediated antibody responses, or they can allow for efficient encapsulation of immunomodulatory molecules as well as immune cells. Immune cells such as DCs can be activated ex vivo in hydrogels prior to their implantation or in vivo by immobilizing stimuli within the gels that would recruit and activate the cells inside the gels, as bioreactors. Localized administration of the immunomodulatory hydrogels next to the tumor site offers higher bioavailability and controlled release of embedded molecules or of factors from embedded/recruited cells, over time. In particular, we have exploited injectable hydrogel-based adhesive scaffolds that can adhere to the surface of a tumor to locally release molecules of interest to combat cancer ( 42 – 45 ).

Future clinical trials will plan to incorporate many/all of the 12 chemokines identified by the molecular signature coupled with appropriate biomaterial scaffolds in an attempt to achieve the “ optimal” lymph node design in immunosuppressed cancer patients.

Author Contributions

All authors contributed to the preparation of this manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding

This study was supported by NCI-NIH (1R01 CA148995, 1R01 CA184845, P30 CA076292, P50 CA168536), Cindy and Jon Gruden Fund, Chris Sullivan Fund, V Foundation, and Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; we thank the staff of the Moffitt Cancer Center Cancer Informatics, Collaborative Data Services, and Tissue Shared Resources.

Footnote

1. ^ Strom T, Harrison LB, Giuliano A, Eschrich SA, Berglund A, Fulp W, et al. Tumor radiosensitivity is associated with tumor-directed immune activation as measured by two gene expression signatures. (Forthcoming).

References

1. Coppola D, Mulé JJ. Ectopic “ lymph nodes” within human solid tumors (invited editorial). J Clin Oncol (2008) 26: 4369–70. doi: 10. 1200/JCO. 2008. 17. 6149

2. Coppola D, Nebozhyn M, Khalil F, Dai H, Yeatman TJ, Loboda A, et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol (2011) 179: 37–45. doi: 10. 1016/j. ajpath. 2011. 03. 007

3. Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep (2012) 2: 765. doi: 10. 1038/srep00765

4. Mihm MC, Mulé JJ. Reflections on the histopathology of tumor-infiltrating lymphocytes in melanoma and the host immune response. Cancer Immunol Res (2015) 3: 827–35. doi: 10. 1158/2326-6066. CIR-15-0143

5. Yin C, Habenicht AJR, Mohanta S, Maffia P. Tertiary Lymphoid Organs (TLOs): Powerhouses of Disease Immunity . Lausanne: Frontiers Media (2017).

6. Hiraoka N, Ino Y, Yamazaki-Itoh R. Tertiary lymphoid organs in cancer tissues. Front Immunol (2016) 7: 244. doi: 10. 3389/fimmu. 2016. 00244

7. Sautes-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH, et al. Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. Front Immunol (2016) 7: 407. doi: 10. 3389/fimmu. 2016. 00407

8. Prabhakaran S, Rizk VT, Ma Z, Cheng C-H, Berglund AE, Coppola D, et al. Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes. Breast Cancer Res (2017)19: 71. doi: 10. 1186/s13058-017-0864-z

9. Dieu-Nosjean MC, Goc J, Giraldo NA, Sautes-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trends Immunol (2014) 35: 571–80. doi: 10. 1016/j. it. 2014. 09. 006

10. Maldonado L, Teague JE, Morrow MP, Jotova I, Wu TC, Wang C, et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med (2014) 6: 221ra13. doi: 10. 1126/scitranslmed. 3007323

11. Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res (2014) 2: 616–31. doi: 10. 1158/2326-6066. CIR-14-0027

12. Moyron-Quiroz JE, Rangel-Moreno J, Hartson L, Kusser K, Tighe MP, Klonowski KD, et al. Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity (2006) 25: 643–54. doi: 10. 1016/j. immuni. 2006. 08. 022

13. Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, et al. Efficacy of adoptive cell transfer of tumor infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother (2012) 35: 615–20. doi: 10. 1097/CJI. 0b013e31826e8f5f

14. Weber JS, Mulé JJ. Cancer immunotherapy meets biomaterials (news and views). Nat Biotechnol (2015) 33: 44–5. doi: 10. 1038/nbt. 3119

15. Fu YX, Chaplin DD. Development and maturation of secondary lymphoid tissues. Annu Rev Immunol (1999) 17: 399–433. doi: 10. 1146/annurev. immunol. 17. 1. 399

16. Alexopoulou L, Pasparakis M, Kollias G. Complementation of lymphotoxin α knockout mice with tumor necrosis factor-expressing transgenes rectifies defective splenic structure and function. J Exp Med (1998) 188: 745–54. doi: 10. 1084/jem. 188. 4. 745

17. Liepinsh DJ, Grivennikov SI, Klarmann KD, Lagarkova MA, Drutskaya MS, Lockett SJ, et al. Novel lymphotoxin alpha (LTα) knockout mice with unperturbed tumor necrosis factor expression: reassessing LTα biological functions. Mol Cell Biol (2006) 26: 4214–25. doi: 10. 1128/MCB. 01751-05

18. Alimzhanov MB, Kuprash DV, Kosco-Vilbois MH, Luz A, Turetskaya RL, Tarakhovsky A, et al. Abnormal development of secondary lymphoid tissues in lymphotoxin β-deficient mice. Proc Natl Acad Sci U S A (1997) 94: 9302–7. doi: 10. 1073/pnas. 94. 17. 9302

19. Drayton DL, Ying X, Lee J, Lesslauer W, Ruddle NH. Ectopic LT alpha beta directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase. J Exp Med (2003) 197: 1153–63. doi: 10. 1084/jem. 20021761

20. Kratz A, Campos-Neto A, Hanson MS, Ruddle NH. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med (1996) 183: 1461–72. doi: 10. 1084/jem. 183. 4. 1461

21. Fan L, Reilly CR, Luo Y, Dorf ME, Lo D. Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis. J Immunol (2000) 164: 3955. doi: 10. 4049/jimmunol. 164. 8. 3955

22. Chen SC, Vassileva G, Kinsley D, Holzmann S, Manfra D, Wiekowski MT, et al. Ectopic expression of the murine chemokines CCL21α and CCL21β induces the formation of lymph node-like structures in pancreas, but not skin, of transgenic mice. J Immunol (2002) 168: 1001–8. doi: 10. 4049/jimmunol. 168. 3. 1001

23. Martin AP, Coronel EC, Sano G, Chen SC, Vassileva G, Canasto-Chibuque C, et al. A novel model for lymphocytic infiltration of the thyroid gland generated by transgenic expression of the CC chemokine CCL21. J Immunol (2004) 173: 4791–8. doi: 10. 4049/jimmunol. 173. 8. 4791

24. Luther SA, Bidgol A, Hargreaves DC, Schmidt A, Xu Y, Paniyadi J, et al. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol (2002) 169: 424–33. doi: 10. 4049/jimmunol. 169. 1. 424

25. Luther SA, Lopez T, Bai W, Hanahan D, Cyster JG. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity (2000) 12: 471–81. doi: 10. 1016/S1074-7613(00)80199-5

26. Kobayashi Y, Watanabe T. Gel-trapped lymphorganogenic chemokines trigger artificial tertiary lymphoid organs and mount adaptive immune responses in vivo. Front Immunol (2016) 7: 316. doi: 10. 3389/fimmu. 2016. 00316

27. Barone F, Gardner DH, Nayar S, Steinthal N, Buckley CD, Luther SA. Stromal fibroblasts in tertiary lymphoid structures: a novel target in chronic inflammation. Front Immunol (2016) 7: 477. doi: 10. 3389/fimmu. 2016. 00477

28. Suematsu S, Watanabe T. Generation of a synthetic lymphoid tissue-like organoid in mice. Nat Biotechnol (2004) 22: 1539–45. doi: 10. 1038/nbt1039

29. Kobayashi Y, Watanabe T. Synthesis of artificial lymphoid tissue with immunological function. Trends Immunol (2010) 31: 422–8. doi: 10. 1016/j. it. 2010. 09. 002

30. Malafaya PB, Silva GA, Reis RL. Natural-origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications. Adv Drug Deliv Rev (2007) 59: 207–33. doi: 10. 1016/j. addr. 2007. 03. 012

31. Irvine DJ, Stachowiak AN, Hori Y. Lymphoid tissue engineering: invoking lymphoid tissue neogenesis in immunotherapy and models of immunity. Semin Immunol (2008) 20: 137–46. doi: 10. 1016/j. smim. 2007. 10. 010

32. Hubbell JA. Biomaterials in tissue engineering. Nat Biotechnol (1995) 13: 565–76. doi: 10. 1038/nbt0695-565

33. Artzi N, Oliva N, Puron C, Shitreet S, Artzi S, bon Ramos A, et al. In vivo and in vitro tracking of erosion in biodegradable materials using non-invasive fluorescence imaging. Nat Mater (2011) 10: 704–9. doi: 10. 1038/nmat3095

34. Unterman S, Freiman A, Beckerman M, Abraham E, Stanley JRL, Levy E, et al. Tuning of collagen scaffold properties modulates embedded endothelial cell regulatory phenotype in repair of vascular injuries in vivo. Adv Healthc Mater (2015) 4: 2220–8. doi: 10. 1002/adhm. 201500457

35. Place ES, George JH, Williams CK, Stevens MM. Synthetic polymer scaffolds for tissue engineering. Chem Soc Rev (2009) 38: 1139–51. doi: 10. 1039/b811392k

36. Dang JM, Leong KW. Natural polymers for gene delivery and tissue engineering. Adv Drug Deliv Rev (2006) 58: 487–99. doi: 10. 1016/j. addr. 2006. 03. 001

37. Read RC, Naylor SC, Potter CW, Bond J, Jabbal-Gill I, Fisher A, et al. Effective nasal influenza vaccine delivery using chitosan. Vaccine (2005) 23: 4367–74. doi: 10. 1016/j. vaccine. 2005. 04. 021

38. McNeela EA, Jabbal-Gill I, Illum L, Pizza M, Rappuoli R, Podda A, et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine (2004) 22: 909–14. doi: 10. 1016/j. vaccine. 2003. 09. 012

39. Tomei AA, Siegert S, Britschgi MR, Luther SA, Swartz MA. Fluid flow regulates stromal cell organization and CCL21 expression in a tissue-engineered lymph node microenvironment. J Immunol (2009) 183: 4273–83. doi: 10. 4049/jimmunol. 0900835

40. Stachowiak AN, Irvine DJ. Inverse opal hydrogel-collagen composite scaffolds as a supportive microenvironment for immune cell migration. J Biomed Mater Res A (2008) 85: 815–28. doi: 10. 1002/jbm. a. 31661

41. Singh A, Peppas NA. Hydrogels and scaffolds for immunomodulation. Adv Mater (2014) 26: 6530–41. doi: 10. 1002/adma. 201402105

42. Gilam A, Conde J, Weissglas-Volkov D, Oliva N, Friedman E, Artzi N, et al. Local microRNA delivery targets Palladin and prevents metastatic breast cancer. Nat Commun (2016) 77: 12868. doi: 10. 1038/ncomms12868

43. Conde J, Oliva N, Zhang Y, Artzi N. Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model. Nat Mater (2016) 15: 1128–38. doi: 10. 1038/nmat4707

44. Conde J, Oliva N, Atilano M, Song HS, Artzi N. Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumor microenvironment. Nat Mater (2016) 15: 353–63. doi: 10. 1038/nmat4497

45. Conde J, Oliva N, Artzi N. Implantable hydrogel embedded dark-gold nanoswitch as a theranostics probe to sense and overcome cancer multidrug resistance. Proc Natl Acad Sci U S A (2015) 112: 1278–87. doi: 10. 1073/pnas. 1421229112